Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM

ENETS Centre of Excellence, Interdisciplinary Center of Neuroendocrine Tumours of the GastroEnteroPancreatic System at the University Hospital of Munich (GEPNET-KUM), University Hospital of Munich, Munich, Germany

Department of Internal Medicine, University Hospital, LMU Munich, Munich, Germany

Matthias Zacherl

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany

Vera Wenter

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany

Michael Winkelmann

Department of Radiology, University Hospital, LMU Munich, Munich, Germany

Jens Ricke

Department of Radiology, University Hospital, LMU Munich, Munich, Germany

Frank Berger

Department of Radiology, University Hospital, LMU Munich, Munich, Germany

Christine Schmid-Tannwald

Christine.schmid-tannwald@med.uni-muenchen.de

Department of Radiology, University Hospital, LMU Munich, Munich, Germany

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/raon-2023-0055 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Page range: 436 - 445

Submitted on: Jun 5, 2023

Accepted on: Sep 25, 2023

Published on: Nov 30, 2023

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

prognosis,

positron emission tomography–computed tomography,

neuroendocrine tumors,

capecitabine/temozolomide

Related subjects:

Medicine,

Clinical medicine,

Internal medicine,

Haematology, oncology,

Radiology

© 2023 Maria Ingenerf, Homeira Karim, Christoph Auernhammer, Matthias Zacherl, Vera Wenter, Michael Winkelmann, Jens Ricke, Frank Berger, Christine Schmid-Tannwald, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 57 (2023): Issue 4 (December 2023)